Use of recombinant human erythropoietin in allogeneic bone marrow transplant donor/recipient pairs

A. Jacqueline Mitus, Joseph H. Antin, Cynthia J. Rutherford, Carol J. McGarigle, Mark A. Goldberg

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

In an attempt to reduce or eliminate homologous red blood cell transfusion requirements during allogeneic bone marrow transplantation (BMT), we instituted a novel program whereby recombinant human erythropoietin was administered to pairs of BMT donors and recipients. Eleven recipients and their HLA-matched donors were enrolled. Donors treated with recombinant human erythropoietin (rHuEPO) were phlebotomized a median of 6 U (range, 4 to 11 U) of blood over a 5-week period. This donor-derived blood was available to the BMT donor or recipient as needed. Transplant recipients were also treated with rHuEPO post-BMT to hasten erythropoiesis. Five of 11 BMT recipients underwent transplant receiving only donor-derived red blood cell transfusions, compared with 0 of 11 concomitant control recipients (P = .04). In addition, the time to absolute reticulocyte count ≥104/μL was statistically shorter in the rHuEPO-treated recipient group. This study serves as a paradigm for hematopoietic growth factor use in allogeneic BMT to decrease or eliminate homologous transfusion exposures and to possibly hasten hematopoietic engraftment.

Original languageEnglish (US)
Pages (from-to)1952-1957
Number of pages6
JournalBlood
Volume83
Issue number7
StatePublished - Apr 1 1994

Fingerprint

Transplants
Erythropoietin
Bone Marrow Transplantation
Bone
Bone Marrow
Tissue Donors
Blood
Erythrocyte Transfusion
Homologous Transplantation
Cells
Reticulocyte Count
Erythropoiesis
Blood Donors
Transplant Recipients
Intercellular Signaling Peptides and Proteins

ASJC Scopus subject areas

  • Hematology

Cite this

Mitus, A. J., Antin, J. H., Rutherford, C. J., McGarigle, C. J., & Goldberg, M. A. (1994). Use of recombinant human erythropoietin in allogeneic bone marrow transplant donor/recipient pairs. Blood, 83(7), 1952-1957.

Use of recombinant human erythropoietin in allogeneic bone marrow transplant donor/recipient pairs. / Mitus, A. Jacqueline; Antin, Joseph H.; Rutherford, Cynthia J.; McGarigle, Carol J.; Goldberg, Mark A.

In: Blood, Vol. 83, No. 7, 01.04.1994, p. 1952-1957.

Research output: Contribution to journalArticle

Mitus, AJ, Antin, JH, Rutherford, CJ, McGarigle, CJ & Goldberg, MA 1994, 'Use of recombinant human erythropoietin in allogeneic bone marrow transplant donor/recipient pairs', Blood, vol. 83, no. 7, pp. 1952-1957.
Mitus, A. Jacqueline ; Antin, Joseph H. ; Rutherford, Cynthia J. ; McGarigle, Carol J. ; Goldberg, Mark A. / Use of recombinant human erythropoietin in allogeneic bone marrow transplant donor/recipient pairs. In: Blood. 1994 ; Vol. 83, No. 7. pp. 1952-1957.
@article{6834c503ae314a58b9752f0b83fd5492,
title = "Use of recombinant human erythropoietin in allogeneic bone marrow transplant donor/recipient pairs",
abstract = "In an attempt to reduce or eliminate homologous red blood cell transfusion requirements during allogeneic bone marrow transplantation (BMT), we instituted a novel program whereby recombinant human erythropoietin was administered to pairs of BMT donors and recipients. Eleven recipients and their HLA-matched donors were enrolled. Donors treated with recombinant human erythropoietin (rHuEPO) were phlebotomized a median of 6 U (range, 4 to 11 U) of blood over a 5-week period. This donor-derived blood was available to the BMT donor or recipient as needed. Transplant recipients were also treated with rHuEPO post-BMT to hasten erythropoiesis. Five of 11 BMT recipients underwent transplant receiving only donor-derived red blood cell transfusions, compared with 0 of 11 concomitant control recipients (P = .04). In addition, the time to absolute reticulocyte count ≥104/μL was statistically shorter in the rHuEPO-treated recipient group. This study serves as a paradigm for hematopoietic growth factor use in allogeneic BMT to decrease or eliminate homologous transfusion exposures and to possibly hasten hematopoietic engraftment.",
author = "Mitus, {A. Jacqueline} and Antin, {Joseph H.} and Rutherford, {Cynthia J.} and McGarigle, {Carol J.} and Goldberg, {Mark A.}",
year = "1994",
month = "4",
day = "1",
language = "English (US)",
volume = "83",
pages = "1952--1957",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Use of recombinant human erythropoietin in allogeneic bone marrow transplant donor/recipient pairs

AU - Mitus, A. Jacqueline

AU - Antin, Joseph H.

AU - Rutherford, Cynthia J.

AU - McGarigle, Carol J.

AU - Goldberg, Mark A.

PY - 1994/4/1

Y1 - 1994/4/1

N2 - In an attempt to reduce or eliminate homologous red blood cell transfusion requirements during allogeneic bone marrow transplantation (BMT), we instituted a novel program whereby recombinant human erythropoietin was administered to pairs of BMT donors and recipients. Eleven recipients and their HLA-matched donors were enrolled. Donors treated with recombinant human erythropoietin (rHuEPO) were phlebotomized a median of 6 U (range, 4 to 11 U) of blood over a 5-week period. This donor-derived blood was available to the BMT donor or recipient as needed. Transplant recipients were also treated with rHuEPO post-BMT to hasten erythropoiesis. Five of 11 BMT recipients underwent transplant receiving only donor-derived red blood cell transfusions, compared with 0 of 11 concomitant control recipients (P = .04). In addition, the time to absolute reticulocyte count ≥104/μL was statistically shorter in the rHuEPO-treated recipient group. This study serves as a paradigm for hematopoietic growth factor use in allogeneic BMT to decrease or eliminate homologous transfusion exposures and to possibly hasten hematopoietic engraftment.

AB - In an attempt to reduce or eliminate homologous red blood cell transfusion requirements during allogeneic bone marrow transplantation (BMT), we instituted a novel program whereby recombinant human erythropoietin was administered to pairs of BMT donors and recipients. Eleven recipients and their HLA-matched donors were enrolled. Donors treated with recombinant human erythropoietin (rHuEPO) were phlebotomized a median of 6 U (range, 4 to 11 U) of blood over a 5-week period. This donor-derived blood was available to the BMT donor or recipient as needed. Transplant recipients were also treated with rHuEPO post-BMT to hasten erythropoiesis. Five of 11 BMT recipients underwent transplant receiving only donor-derived red blood cell transfusions, compared with 0 of 11 concomitant control recipients (P = .04). In addition, the time to absolute reticulocyte count ≥104/μL was statistically shorter in the rHuEPO-treated recipient group. This study serves as a paradigm for hematopoietic growth factor use in allogeneic BMT to decrease or eliminate homologous transfusion exposures and to possibly hasten hematopoietic engraftment.

UR - http://www.scopus.com/inward/record.url?scp=0028350481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028350481&partnerID=8YFLogxK

M3 - Article

C2 - 8142661

AN - SCOPUS:0028350481

VL - 83

SP - 1952

EP - 1957

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -